Table 1 Comparison of demographic and clinical data for RA patients enrolled in the national database by 88 rheumatological units with those from a sample of nine selected units (unit sample) and those from the osteoporosis module subsample
DemographyNDBUnit sampleOM subsample
No of cases12 28837921066
Female77%79%79%
Age, in years (mean, SD)59.6 (12.9)59.4 (13.1)59.9 (12.2)
Disease duration, in years (mean, SD)10.7 (9.7)10.7 (9.7)11.5 (10.0)
High disease activity* (score 7–10)7%8%8%
High disease severity† (severe, very severe)17%16%15%
Current DMARD therapy82%82%85%
Complementary current drug therapy90%90%93%
Current glucocorticoid therapy, mg/day
    ⩽7.545.9%45.6%50.8%
    >7.510.4%9.8%8.5%
Patient-derived data:
    High pain* (score 7–10)26%27%29%
    Poor general health* (score 7–10)24%25%27%
    low functional capacity‡ (HAQ >1.75)23%24%28%
    No of comorbidities (mean, SD)2.2 (2.0)2.3 (2.1)2.4 (2.1)
  • *Numeric rating scale from 0  =  best to 10  =  worst. †Categorical five-point scale “asymptomatic”, “light”, “moderate”, “severe”, “very severe”. ‡Measured by the Funktionsfragebogen Hannover (FFbH), a health assessment questionnaire (HAQ)-like, convertible instrument measuring functional limitation in activities of daily living on a scale from 0 to 100.11 DMARD, disease-modifying antirheumatic drug; NDB, national database; OM, osteoporosis module; RA, rheumatoid arthritis.